Funding will accelerate commercialization and US lumbar trial for the iFACTOR Peptide Enhanced Bone Graft, a unique drug-device technology enhances the body's natural bone healing process through cellular activity that is directional and predictable.
The i(FACTOR Peptide Enhanced Bone Graft is based on proprietary biomimetic small peptide technology that has a novel mechanism of action (attract, attach, and activate) that induces osteoblast cell proliferation and differentiation to accelerate new bone formation in patients with degenerative disc disease.
Cerapedics received Premarket Approval from the US FDA for the use of i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion procedures. The company has also initiated an IDE clinical trial in transforaminal lumbar interbody fusion surgery.
Privately held Cerapedics is focused on developing and commercializing its proprietary synthetic small peptide technology platform.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon